{"id":11436,"date":"2023-11-17T22:37:00","date_gmt":"2023-11-17T14:37:00","guid":{"rendered":"https:\/\/flcube.com\/?p=11436"},"modified":"2024-11-05T22:41:06","modified_gmt":"2024-11-05T14:41:06","slug":"visen-pharmaceuticals-reports-positive-phase-ii-results-for-transcon-cnp-in-achondroplasia","status":"publish","type":"post","link":"https:\/\/flcube.com\/?p=11436","title":{"rendered":"Visen Pharmaceuticals Reports Positive Phase II Results for TransCon CNP in Achondroplasia"},"content":{"rendered":"\n<p class=\"wp-block-paragraph\">Visen Pharmaceuticals, a joint venture between Denmark-based Ascendis Pharma A\/S (<a href=\"https:\/\/www.google.com\/finance\/quote\/ASND:NASDAQ\">NASDAQ: ASND<\/a>) and Chinese healthcare investment firm Vivo Capital, has announced topline results from the ACcomplisH China Phase II trial. The study assessed the safety and efficacy of once-weekly TransCon CNP (navepegritide) in children with achondroplasia (ACH) aged 2 to 10 years in China. CNP, or C-type natriuretic peptide, is a naturally occurring peptide that regulates bone growth and has shown potential in treating growth and skeletal disorders such as dwarfism.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">Patients dosed with TransCon CNP at the 100 \u03bcg CNP\/kg\/week demonstrated significantly higher annualized growth velocity (AGV) compared to placebo, with an AGV of 1.180 cm\/year at Week 52 (P=0.018).<\/p>\n\n\n\n<p class=\"wp-block-paragraph\"><strong>Achondroplasia&#8217;s Global Impact and Treatment Landscape<\/strong><\/p>\n\n\n\n<p class=\"wp-block-paragraph\">ACH, the most common form of skeletal dysplasia, affects approximately 250,000 people worldwide. Individuals with ACH may experience severe skeletal complications and comorbidities, including sleep apnea, chronic back and leg pain, and in severe cases, sudden infant death from cervical compression. ACH is included in China&#8217;s second batch of rare disease list.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">TransCon CNP, globally owned and developed by Ascendis Pharma, is undergoing a global randomized, double-blind, placebo-controlled Phase III pivotal study involving 80 ACH children aged 2 to 11. Visen holds exclusive rights for the development, manufacturing, and commercialization of TransCon CNP, human growth hormone (hGH), and parathyroid hormone in Greater China.- <a href=\"https:\/\/flcube.com\">Flcube.com<\/a><\/p>\n\n\n\n<p class=\"wp-block-paragraph\"><\/p>\n","protected":false},"excerpt":{"rendered":"<p>Visen Pharmaceuticals, a joint venture between Denmark-based Ascendis Pharma A\/S (NASDAQ: ASND) and Chinese healthcare&#8230;<\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"googlesitekit_rrm_CAownpewDA:productID":"","_jetpack_newsletter_access":"","_jetpack_dont_email_post_to_subs":false,"_jetpack_newsletter_tier_id":0,"_jetpack_memberships_contains_paywalled_content":false,"_jetpack_feature_clip_id":0,"_jetpack_memberships_contains_paid_content":false,"footnotes":"","jetpack_publicize_message":"","jetpack_publicize_feature_enabled":true,"jetpack_social_post_already_shared":false,"jetpack_social_options":{"image_generator_settings":{"template":"highway","default_image_id":0,"font":"","enabled":false},"version":2},"jetpack_post_was_ever_published":false},"categories":[7,11],"tags":[392,17,1195,393],"class_list":["post-11436","post","type-post","status-publish","format-standard","hentry","category-company","category-drug","tag-ascendis-pharma","tag-clinical-trial-results","tag-nasdaq-asnd","tag-visen-pharmaceuticals"],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v27.5 (Yoast SEO v27.9) - https:\/\/yoast.com\/product\/yoast-seo-premium-wordpress\/ -->\n<title>Visen Pharmaceuticals Reports Positive Phase II Results for TransCon CNP in Achondroplasia - Insight, China&#039;s Pharmaceutical Industry<\/title>\n<meta name=\"description\" content=\"Visen Pharmaceuticals, a joint venture between Denmark-based Ascendis Pharma A\/S (NASDAQ: ASND) and Chinese healthcare investment firm Vivo Capital, has announced topline results from the ACcomplisH China Phase II trial. The study assessed the safety and efficacy of once-weekly TransCon CNP (navepegritide) in children with achondroplasia (ACH) aged 2 to 10 years in China. CNP, or C-type natriuretic peptide, is a naturally occurring peptide that regulates bone growth and has shown potential in treating growth and skeletal disorders such as dwarfism.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/flcube.com\/?p=11436\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Visen Pharmaceuticals Reports Positive Phase II Results for TransCon CNP in Achondroplasia\" \/>\n<meta property=\"og:description\" content=\"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM\" \/>\n<meta property=\"og:url\" content=\"https:\/\/flcube.com\/?p=11436\" \/>\n<meta property=\"og:site_name\" content=\"Insight, China&#039;s Pharmaceutical Industry\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/profile.php?id=61566606313834\" \/>\n<meta property=\"article:published_time\" content=\"2023-11-17T14:37:00+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2024-11-05T14:41:06+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"2560\" \/>\n\t<meta property=\"og:image:height\" content=\"1894\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"Fineline Cube\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Fineline Cube\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"1 minute\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=11436#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=11436\"},\"author\":{\"name\":\"Fineline Cube\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\"},\"headline\":\"Visen Pharmaceuticals Reports Positive Phase II Results for TransCon CNP in Achondroplasia\",\"datePublished\":\"2023-11-17T14:37:00+00:00\",\"dateModified\":\"2024-11-05T14:41:06+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=11436\"},\"wordCount\":232,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"keywords\":[\"Ascendis Pharma\",\"Clinical trial results\",\"NASDAQ: ASND\",\"Visen Pharmaceuticals\"],\"articleSection\":[\"Company\",\"Drug\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=11436#respond\"]}],\"copyrightYear\":\"2023\",\"copyrightHolder\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"}},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=11436\",\"url\":\"https:\\\/\\\/flcube.com\\\/?p=11436\",\"name\":\"Visen Pharmaceuticals Reports Positive Phase II Results for TransCon CNP in Achondroplasia - Insight, China&#039;s Pharmaceutical Industry\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\"},\"datePublished\":\"2023-11-17T14:37:00+00:00\",\"dateModified\":\"2024-11-05T14:41:06+00:00\",\"description\":\"Visen Pharmaceuticals, a joint venture between Denmark-based Ascendis Pharma A\\\/S (NASDAQ: ASND) and Chinese healthcare investment firm Vivo Capital, has announced topline results from the ACcomplisH China Phase II trial. The study assessed the safety and efficacy of once-weekly TransCon CNP (navepegritide) in children with achondroplasia (ACH) aged 2 to 10 years in China. CNP, or C-type natriuretic peptide, is a naturally occurring peptide that regulates bone growth and has shown potential in treating growth and skeletal disorders such as dwarfism.\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=11436#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=11436\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=11436#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/flcube.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Visen Pharmaceuticals Reports Positive Phase II Results for TransCon CNP in Achondroplasia\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"name\":\"Insight, China's Pharmaceutical Industry\",\"description\":\"Fineline Insights, Pharma Clarity\",\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/flcube.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\",\"name\":\"Fineline Infomation and Technology\",\"alternateName\":\"Fineline Info & Tech\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"width\":2560,\"height\":1894,\"caption\":\"Fineline Infomation and Technology\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/profile.php?id=61566606313834\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\",\"name\":\"Fineline Cube\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"caption\":\"Fineline Cube\"},\"sameAs\":[\"https:\\\/\\\/flcube.com\"],\"url\":\"https:\\\/\\\/flcube.com\\\/?author=1\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Visen Pharmaceuticals Reports Positive Phase II Results for TransCon CNP in Achondroplasia - Insight, China&#039;s Pharmaceutical Industry","description":"Visen Pharmaceuticals, a joint venture between Denmark-based Ascendis Pharma A\/S (NASDAQ: ASND) and Chinese healthcare investment firm Vivo Capital, has announced topline results from the ACcomplisH China Phase II trial. The study assessed the safety and efficacy of once-weekly TransCon CNP (navepegritide) in children with achondroplasia (ACH) aged 2 to 10 years in China. CNP, or C-type natriuretic peptide, is a naturally occurring peptide that regulates bone growth and has shown potential in treating growth and skeletal disorders such as dwarfism.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/flcube.com\/?p=11436","og_locale":"en_US","og_type":"article","og_title":"Visen Pharmaceuticals Reports Positive Phase II Results for TransCon CNP in Achondroplasia","og_description":"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM","og_url":"https:\/\/flcube.com\/?p=11436","og_site_name":"Insight, China&#039;s Pharmaceutical Industry","article_publisher":"https:\/\/www.facebook.com\/profile.php?id=61566606313834","article_published_time":"2023-11-17T14:37:00+00:00","article_modified_time":"2024-11-05T14:41:06+00:00","og_image":[{"width":2560,"height":1894,"url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","type":"image\/jpeg"}],"author":"Fineline Cube","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Fineline Cube","Est. reading time":"1 minute"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/flcube.com\/?p=11436#article","isPartOf":{"@id":"https:\/\/flcube.com\/?p=11436"},"author":{"name":"Fineline Cube","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a"},"headline":"Visen Pharmaceuticals Reports Positive Phase II Results for TransCon CNP in Achondroplasia","datePublished":"2023-11-17T14:37:00+00:00","dateModified":"2024-11-05T14:41:06+00:00","mainEntityOfPage":{"@id":"https:\/\/flcube.com\/?p=11436"},"wordCount":232,"commentCount":0,"publisher":{"@id":"https:\/\/flcube.com\/#organization"},"keywords":["Ascendis Pharma","Clinical trial results","NASDAQ: ASND","Visen Pharmaceuticals"],"articleSection":["Company","Drug"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/flcube.com\/?p=11436#respond"]}],"copyrightYear":"2023","copyrightHolder":{"@id":"https:\/\/flcube.com\/#organization"}},{"@type":"WebPage","@id":"https:\/\/flcube.com\/?p=11436","url":"https:\/\/flcube.com\/?p=11436","name":"Visen Pharmaceuticals Reports Positive Phase II Results for TransCon CNP in Achondroplasia - Insight, China&#039;s Pharmaceutical Industry","isPartOf":{"@id":"https:\/\/flcube.com\/#website"},"datePublished":"2023-11-17T14:37:00+00:00","dateModified":"2024-11-05T14:41:06+00:00","description":"Visen Pharmaceuticals, a joint venture between Denmark-based Ascendis Pharma A\/S (NASDAQ: ASND) and Chinese healthcare investment firm Vivo Capital, has announced topline results from the ACcomplisH China Phase II trial. The study assessed the safety and efficacy of once-weekly TransCon CNP (navepegritide) in children with achondroplasia (ACH) aged 2 to 10 years in China. CNP, or C-type natriuretic peptide, is a naturally occurring peptide that regulates bone growth and has shown potential in treating growth and skeletal disorders such as dwarfism.","breadcrumb":{"@id":"https:\/\/flcube.com\/?p=11436#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/flcube.com\/?p=11436"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/flcube.com\/?p=11436#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/flcube.com\/"},{"@type":"ListItem","position":2,"name":"Visen Pharmaceuticals Reports Positive Phase II Results for TransCon CNP in Achondroplasia"}]},{"@type":"WebSite","@id":"https:\/\/flcube.com\/#website","url":"https:\/\/flcube.com\/","name":"Insight, China's Pharmaceutical Industry","description":"Fineline Insights, Pharma Clarity","publisher":{"@id":"https:\/\/flcube.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/flcube.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/flcube.com\/#organization","name":"Fineline Infomation and Technology","alternateName":"Fineline Info & Tech","url":"https:\/\/flcube.com\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/","url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","width":2560,"height":1894,"caption":"Fineline Infomation and Technology"},"image":{"@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/profile.php?id=61566606313834"]},{"@type":"Person","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a","name":"Fineline Cube","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","caption":"Fineline Cube"},"sameAs":["https:\/\/flcube.com"],"url":"https:\/\/flcube.com\/?author=1"}]}},"jetpack_publicize_connections":[],"jetpack_featured_media_url":"","jetpack_sharing_enabled":true,"_links":{"self":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/11436","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=11436"}],"version-history":[{"count":1,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/11436\/revisions"}],"predecessor-version":[{"id":11437,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/11436\/revisions\/11437"}],"wp:attachment":[{"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=11436"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=11436"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=11436"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}